Figure 1
PD‐L1 expressions were analyzed in BC tissue samples and cell lines. (a) PD-L1 expression was upregulated in BC tissues (n = 50) as compared with normal samples using qRT‐PCR (b) Shows PD-L1 mRNA expression in normal and breast cancer tissues using TCGA database (c) The relationship between PD-L1 expression and clinical pathologic features (d) The Kaplan–Meier plotter shows the prognostic role of PD-L1 mRNA expression in progression-free survival (e) The Kaplan–Meier plotter for overall survival shows the prognostic role of PD-L1 mRNA expression in breast cancer (f) Immunohistochemical staining of PD-L1 (I) in breast cancer tissue and (II) in breast non-cancerous tissue (g) Area under the curve (AUC) and receiver operating characteristics (ROC) for PD-L1 (h) The correlation between PD-L1 expression with TNBC and non-TNBC status of the tumor (i) PDL1 expression in BC cell lines compared to normal breast cell line; ***P ≤ 0.001; **P ≤ 0.01; ns = non-significant. The results were expressed as the mean ± SE of the experiments. PD‐L1, programmed death-ligand 1; qRT‐PCR, quantitative reverse transcription-PCR; TP, Tumor Patient; NTP, Non-Tumor Patient.
